Arteriosclerosis
Not recruitingStudy on Inclisiran for Preventing Heart Disease in High-Risk Patients
- Disease:Arteriosclerosis
- Substances:Inclisiran
Estonia- Participants:18–64 years · 65+ years
- Substances:Inclisiran
- Sponsor:Novartis Pharma AG
Rare diseases
Investigational molecules
Locations
Back to Estonia143 clinical trials in Tartu, Estonia across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in EstoniaKliinilisedUuringud.ee(opens in a new tab)
Estonia
Estonia
Estonia
Estonia
Estonia
Estonia
Estonia
Estonia
Estonia
Estonia
Estonia
EstoniaThe busiest research cities in the country
What the registry says about research in the country
Several trials focusing on innovative treatments for autoimmune disorders, particularly investigating new therapies for psoriatic arthritis and plaque psoriasis. Research includes testing of novel compounds like zasocitinib and evaluating long-term safety profiles.
Studies aim to improve disease management and patient outcomes through targeted therapies.
Comprehensive cancer research programs examining treatments for various types of lung cancer and other malignancies. Studies focus on combination therapies and novel treatment approaches.
Emphasis on immunotherapy combinations and targeted treatments for better patient outcomes.
Investigation of treatments for osteoporosis and related conditions, with a focus on postmenopausal women and innovative therapeutic approaches.
Research aims to improve bone health and manage metabolic conditions through new therapeutic options.
Tell us about your condition – we search every trial in Europe and connect you with the right site.